Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 6, 1997, Pages 495-505

  Levasseur, Laurence M ^a   Greco, William R ^a   Rustum, Youcef M ^a   Slocum, Harry K ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Isobol; Surface modeling; Taxol

Indexed keywords

CISPLATIN; PACLITAXEL;

ARTICLE; CARCINOMA CELL; CELL GROWTH; CELL LINE; CONTROLLED STUDY; DRUG RESISTANCE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; ILEUM CANCER; IN VITRO STUDY; OVARY CARCINOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIVISION; CISPLATIN; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 0030860270     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050693     Document Type: Article

References (46)

1. Ajani JA, Ilson DH, Kelsen DP (1995) The activity of paclitaxel in gastrointestinal tumors. Semin Oncol 22 [Suppl 12]: 46
2. Chou TC, Motzer RJ, Tong Y, Bosl GJ (1994) Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517
3. Chu QD, Shrayer DP, Wanebo HJ (1995) Biophasic effect of cisplatin and taxol on B16 F10 melanoma. Proc Am Assoc Cancer Res 36: A2218
4. Crickard K, Niedbala MJ, Crickard U, Yoonessi M, Sandberg AA, Okuyama K, Bernacki RJ, Satchidanand SK (1989) Characterization of human ovarian and endometrial carcinoma cell lines established on extracellular matrix. Gynecol Oncol 32: 163
5. DeVita VT (1993) Principles of chemotherapy. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practices of oncology, 4th edn. JB Lippincott, Philadelphia, p 276
6. Faessel H, Slocum HK, Jackson RC, Boritzki T, Rustum YM, Greco WR (1996) Super in vitro synergy between trimetrexate and the polyglutamylatable antifolates AG2034, AG2032, AG2009 and Tomudex against human HCT-8 colon cells. Proc Am Assoc Cancer Res 37: A2629
7. Forastiere AA (1994) Current and future trials of taxol (paclitaxel) in head and neck cancer. Ann Oncol 5: S51
8. Gaumont Y, Kisliuk RL, Parsons JC, Greco WR (1992) Quantitation of folic acid enhancement of antifolate synergism. Cancer Res 52: 2228
9. Gercel-Taylor C, Taylor D, Owens K (1994) Effect of sequencing with taxol on cisplatin sensitivity of ovarian cancer cell lines. Proc Am Assoc Cancer Res 35: A1959
10. Gessner PK (1974) The isobolographic method applied to drug interactions. In: Morselli PL, Garattini S, Cohen SN (eds) Drug interactions. Raven Press, New York, p 349
11. Giard DJ, Aaronson SA, Todaro GJ, Kersey JH, Dosik H, Parks WP (1973) In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51: 1417
12. Glück S, Sharan N, Chadderton T, Dietz G, Bewick M, Köster W, Lutynski A, Gallant G (1994) In vitro combination of paclitaxel (Taxol®, TXL) with 5 different cytotoxic drugs: effect on three different cell lines. Proc Am Assoc Cancer Res 35: A1992
13. Greco FA (1996) Urogenital and gynecologic cancer. In: Greco FA (ed) Handbook of commonly used chemotherapy regimens. A quick reference guide to more than 100 current cytotoxic therapies. Precept Press, Chicago, p 137
14. Greco WR, Park HS, Rustum YM (1990) An application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-β-D-arabinofuranosylcytosine. Cancer Res 50: 5318
15. Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47: 331
16. Greene RF, Chatterji DC, Hiranaka PK, Galleli JF (1979) Stability of cisplatin in aqueous solution. Am J Hosp Pharm 36: 38
17. Grunwald J (1987) Time-lapse video microscopic analysis of cell proliferation, motility and morphology: applications for cytopathology and pharmacology. Biotechniques 5: 680
18. Hortobagyi GN (1995) Management of breast cancer: status and future trends. Semin Oncol 22: 101
19. Jamali MAA, Yin MB, Mazzoni A, Bankusli I, Rustum YM (1989) Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: modulation by the tiapamil analog RO11-2933. Cancer Chemother Pharmacol 25: 77
20. Jekunen AP, Christen RD, Shalinsky DR, Howell SB (1994) Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 69: 299
21. Johnson DH (1995) Phase III trial (E5592) comparing cisplatin plus etoposide with cisplatin plus paclitaxel at two dose levels for treatment of advanced non-small-cell lung cancer. Eastern Cooperative Oncology group. Monogr Natl Cancer Inst 19: 61
22. Kano Y, Akutsu M, Tsunoda S, Suzuki K, Yazawa Y (1996) In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines. Cancer Chemother Pharmacol 37: 525
23. Kern DH, Morgan CR (1993) Apparent in vitro antagonism between cisplatin and taxol. Proc Am Assoc Cancer Res 34: A1788
24. LeBlanc GA, Sundseth SS, Weber GF, Waxman DJ (1992) Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res 52: 540
25. Levasseur L, Faessel H, Slocum HK, Greco WR (1995) Precision and pattern in 96-well plate cell growth experiments. Proc Biopharm Sect Am Stat Assoc: 227
26. Liebmann JE, Fisher J, Teague D, Cook JA (1994) Sequence-dependence of paclitaxel (Taxol®) combined with cisplatin or alkylators in human cancer cells. Oncol Res 6: 25
27. Lopes NM, Adams EG, Pitts TW, Bhuyan BK (1993) Cell cycle kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32: 235
28. Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, Hamilton TC (1988) Increased DNA repair as a mechanism of acquired resistance to cisdiamminedichloroplatinum(II) in human ovarian cancer cell lines. Cancer Res 48: 5713
29. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge DE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1
30. Parker RJ, Dabholkar MD, Lee KB, Bostick-Bruton F, Reed E (1993) Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. Monogr Natl Cancer Inst 15: 83
31. Parker RJ, Lee KB, Dabholkar M, Bostick-Bruton F, Simms M, Reed E (1993) Influence of taxol: cisplatin sequencing on cisplatin-DNA adduct repair in human ovarian cancer cells. Proc Am Assoc Cancer Res 34: A2122
32. Peyrot V, Briand C, Crevat A, Braguer D, Chauvet-Monges AM, Sari JC (1983) Action of hydrolyzed cisplatin and some analogs on microtubule protein polymerization in vitro. Cancer Treat Rep 67: 641
33. Rangan SRS (1972) A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer 29: 117
34. Reed E, Kohn EC, Sarosy G, Dabholkar M, Davis P, Jacob J, Maher M (1995) Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Semin Oncol 22: 90
35. Reed E, Dabholkar M, Chabner BA (1996) Platinum analogues. In: Chabner BA, Longo DL (eds) Cancer chemotherapy and biotherapy: principles and practice. Lippincott-Raven, Philadelphia New York, p 357
36. Rogan AM, Hamilton TC, Young RC, Klecker RW, Ozols RF (1984) Reversal of adriamycine resistance by verapamil in human ovarian cancer. Science 224: 994
37. Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247
38. Rowinsky EK, Gilbert M, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, Cornblath DR, Hendricks CB, Donehower RC (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9: 1692
39. Rowinsky EK, Citardi MJ, Noe DA, Donehower RC (1993) Sequence-dependent cytotoxic effects due to the combinations of cisplatin and antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 119: 727
40. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107
41. Slocum HK, Malmberg M, Greco WR, Parsons JC, Rustum YM (1990) The determination of growth rates of individual colonies in agarose using high resolution automated image analysis. Cytometry 11: 793
42. Thigpen T, Vance R, Puneky L, Khansur T (1994) Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol 55: S97
43. Thigpen T, Vance RB, Khansur T (1995) The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol 22 [Suppl 12]: 67
44. Untch M, Sevin BU, Perras JP, Angioli R, Untch A, Hightower RD, Koechli O, Averette HE (1994) Evaluation of paclitaxel (Taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay. Gynecol Oncol 53: 44
45. Vanhoefer U, Harstrick A, Wilke H, Schleucher N, Walks H, Schröder J, Seeber S (1995) Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer 31A: 92
46. Viallet J, Boucher L, Gallant G (1994) In vitro interactions between paclitaxel (TAX) and other agents in human non small cell lung cancer (NSCLC) cell lines: antagonism with etoposide (VP-160) and doxorubicin (DOX). Proc Am Soc Clin Oncol 13: A1233